MENU
Showcases Stock ranks Forex

Evofem Biosciences Inc (EVFM)
0.0154  0.001 (9.22%) 04-19 15:59
Open: 0.0141 Pre. Close: 0.0141
High: 0.0159 Low: 0.0141
Volume: 369,086 Market Cap: 3(M)
Stock Technical Analysis
Overall:     
Target: Six months: 0.03
One year: 0.04
Support: Support1: 0.01
Support2: 0.01
Resistance: Resistance1: 0.03
Resistance2: 0.04
Pivot: 0.02
Moving Averages: MA(5): 0.02
MA(20): 0.02
MA(100): 0.04
MA(250): 0.24
MACD: MACD(12,26):
Signal(12,26,9):
%K %D: %K(14,3): 7.10
%D(3): 8.72
RSI: RSI(14): 39.51
52-Week: High: 3.875
Low: 0.012
Change(%): -96.2
Average Vol(K): 3-Month: 4229
10-Days: 4497
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.02 - 0.02 0.02 - 0.02
Low: 0.01 - 0.01 0.01 - 0.01
Close: 0.02 - 0.02 0.02 - 0.02
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ EVFM ] has closed above bottom band by 17.7%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Stock chart
Stock News
Thu, 18 Apr 2024
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO – Company ... - Financial Times

Sun, 14 Apr 2024
Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't? - Yahoo Movies Canada

Thu, 28 Mar 2024
Evofem Biosciences Issues Update with Latest Presentation - TipRanks.com - TipRanks

Wed, 27 Mar 2024
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q4 2023 - InvestorPlace

Wed, 27 Mar 2024
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - BioSpace

Thu, 01 Feb 2024
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PR Newswire

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  Other OTC
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 215.96
Shares Float (M)
% Held by Insiders 0.14
% Held by Institutions 4.46
Shares Short (K) 8680
Shares Short Prior Month (K) 17820
Stock Financials
EPS -1.400
Book Value (p.s.) -0.760
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) 0.058
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio -0.01
PEG Ratio
Price to Book value -0.02
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android